HLJ2 Effectively Ameliorates Colitis-Associated Cancer via Inhibition of NF-κB and Epithelial-Mesenchymal Transition
Related Experiment Video
Updated: Dec 3, 2025
Huachen Song1, Xiaonan Tang1, Xiang Li1
1State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, People's Republic of China.
Introduction:
Colitis-associated cancer (CAC) accounts for approximately 15% of IBD patient mortalities. However, currently available anti-CAC drugs possess many disadvantages including safety, specificity and side effects. Therefore, the development of novel anti-CAC compounds is imperative. HLJ2 was a monomeric compound synthesized by our institute and reported to have an effect on ulcer colitis.
Methods:
In vivo the AOM/DSS-induced CAC model was used to evaluate the effects of HLJ2 on ameliorating CAC symptoms, immunohistochemical analysis was used to analyze the pathological damage to colons and epithelial-mesenchymal transition was for changes of cytokines. In vitro, flow cytometric analysis, immunofluorescence and Western blot were used to detect the inhibition effect of HLJ2 on nuclear factor-κB and epithelial-mesenchymal transition in TGF-β1-stimulated SW480 cells.
Results:
In the AOM/DSS animal model, HLJ2 was demonstrated to inhibit the secretion of inflammatory cytokines and nuclear factor-κB, levels of tumorigenesis-related proteins including snail, and finally inhibited a key step in metastasis, epithelial-mesenchymal transition. In vitro, HLJ2 was also shown to inhibit nuclear factor-κB and epithelial-mesenchymal transition in TGF-β1-stimulated SW480 cells in accordance with in vivo results. Meanwhile, the nuclear factor-κB inhibitor could interrupt the effect of HLJ2 on epithelial-mesenchymal transition.
Discussion:
HLJ2 may ameliorate CAC through inhibiting nuclear factor-κB and then downstream epithelial-mesenchymal transition. The combination of the obvious improvement in effects on CAC without obvious side effects suggests that HLJ2 could be developed as a potential CAC therapeutic candidate.
Insights
HLJ2 shows promise as a novel therapeutic for colitis-associated cancer (CAC). This compound inhibits key pathways like nuclear factor-κB and epithelial-mesenchymal transition, crucial for cancer progression and metastasis.
Area of Science:
- Gastroenterology
- Oncology
- Molecular Biology
Background:
- Colitis-associated cancer (CAC) is a significant cause of mortality in IBD patients.
- Existing anti-CAC drugs have limitations in safety, specificity, and side effects.
- Novel therapeutic candidates for CAC are urgently needed.
Purpose of the Study:
- To investigate the therapeutic potential of HLJ2, a novel synthesized compound, for ameliorating CAC.
- To elucidate the underlying mechanisms of HLJ2's action in CAC models.
Main Methods:
- An in vivo AOM/DSS-induced CAC model was employed to assess HLJ2's efficacy.
- Immunohistochemistry and Western blot analyses were used to evaluate pathological damage and molecular changes.
- In vitro studies utilized TGF-β1-stimulated SW480 cells to examine HLJ2's effects on nuclear factor-κB (NF-κB) and epithelial-mesenchymal transition (EMT).
Main Results:
- HLJ2 significantly inhibited pro-inflammatory cytokines and NF-κB in the AOM/DSS model.
- The compound suppressed EMT and key metastasis-related proteins, including snail.
- In vitro, HLJ2 demonstrated inhibition of NF-κB and EMT in TGF-β1-stimulated cells, consistent with in vivo findings.
Conclusions:
- HLJ2 ameliorates CAC by inhibiting NF-κB and downstream EMT.
- HLJ2 presents a potential therapeutic candidate for CAC with significant efficacy and minimal side effects.
More Related Videos
06:31Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids
Published on: June 2, 2023
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Related Concept Videos
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Drugs for Treatment of Ulcerative Colitis in IBD
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
